December 27, 2017
Authored and Edited by Jonathan Uffelman; Naresh Kilaru; Julia Anne Matheson
Boehringer Ingelheim Pharmaceuticals, Inc. sought to register the mark BREATHLESS for “promoting public awareness of idiopathic pulmonary fibrosis [‘IPF’], its symptoms, its prevention and its treatment.” The Examining Attorney refused registration on the basis that the mark was merely descriptive of Boehringer’s services. The TTAB reversed.
The Board noted that one dictionary defines “breathless” as “[b]reathing with difficulty, gasping” and “excited or tense, often to the point of holding the breath: a breathless audience.” Boehringer argued its applied-for mark was suggestive, rather than merely descriptive, applying either definition. According to Boehringer, to connect promotional awareness and information services with the concept that IPF causes patients to become “breathless” requires a multi-step reasoning process. Applying the second definition, Boehringer argued BREATHLESS was a double entendre because it refers to the anticipation patients and their loved ones feel about the progress being made in preventing or treating IPF. The Examining Attorney, on the other hand, argued that BREATHLESS was descriptive of the information Boehringer provided because consumers would immediately understand the mark to describe the main symptom of IPF.
The Board agreed with Boehringer. According to the Board, the Examining Attorney’s “evidence fail[ed] to demonstrate[] that the term ‘breathless’ merely describes providing consumers with information about IPF or raising public awareness of IPF. . . . Specifically, BREATHLESS does not identify a feature of the services themselves or convey information about Applicant’s promotional and medical information services.” In short, the applied-for mark contained “an element of incompleteness” that made it suggestive.
The Board, however, took pains to note that this was a “close case” and stressed that its decision was based solely on Boehringer’s identification of services and the “quite limited record presented by the Examining attorney.” The Board specifically stated that “[a]nyone who believes that the term BREATHLESS is, in fact, merely descriptive, may oppose the application and have the opportunity to present a more complete record in an inter partes proceeding.”
The case is In re Boehringer Ingelheim Pharmaceuticals, Inc., Serial No. 86852106 (TTAB Nov. 27, 2017).
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
INCONTESTABLE® Blog
April 12, 2024
INCONTESTABLE® Blog
April 4, 2024
INCONTESTABLE® Blog
Winning the Battle but Not the War: Disclaimer Requirement Overturned, Section 2(d) Objection Upheld
March 28, 2024
INCONTESTABLE® Blog
The Federal Circuit’s Heartfelt Affirmation of Everybody’s Right to Use “Everybody vs. Racism”
March 22, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.